|Bid||0.00000 x 0|
|Ask||0.00000 x 0|
|Day's Range||0.6125 - 0.9050|
|52 Week Range||0.6125 - 10.2900|
|Beta (3Y Monthly)||-12.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, Oct. 23, 2018 -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that.
(“AXIM® Biotech” or “AXIM”) (AXIM), a world leader in cannabinoid research and development, today announced that it has received a manufacturing license from the Dutch Ministry of Health, Welfare and Sports for the production, according to Good Manufacturing Practices (“GMP”), of the company’s pharmaceutical products to be used in clinical trials. Effective Oct. 1, 2018, the license allows AXIM to produce its cannabinoid-based pharmaceutical drug candidates for use in human clinical trials for multiple indications.
OTC:AXIM Summary • AXIM Biotechnologies (OTC:AXIM) holds the intellectual property rights to the controlled-release, trans-mucosal (chewing gum) drug delivery platform for medical cannabinoids. o The company ...
SAN DIEGO , Feb. 28, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States , announced that its major investment company AXIM® ...
As marijuana legalization begins to slowly roll out state by state, it follows that marijuana-based businesses have cropped up, and many are trying their hand in the public markets. Regrettably, CANN is losing more and more money on marijuana services every year and is also burning cash.